Stockscreener 앱 받기
111.42
1.74%
1.91
시간 외 거래:
111.31
-0.11
-0.10%
전일 마감가:
$109.51
열려 있는:
$111.05
하루 거래량:
554.14K
Relative Volume:
0.81
시가총액:
$4.65B
수익:
-
순이익/손실:
-
주가수익비율:
-118.53
EPS:
-0.94
순현금흐름:
-
1주 성능:
+5.07%
1개월 성능:
-12.19%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$110.25
$116.09
1주일 범위
$106.83
$117.93
52주 변동 폭
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
명칭
Veradermics Inc
전화
228.372.3376
주소
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
111.42 | 4.58B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-02 | 개시 | Citigroup | Buy |
| 2026-03-02 | 개시 | Jefferies | Buy |
| 2026-03-02 | 개시 | Leerink Partners | Outperform |
Veradermics Inc 주식(MANE)의 최신 뉴스
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - MSN
Veradermics presents subgroup analysis of hair loss drug trial By Investing.com - Investing.com Canada
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
Veradermics Is Maintained at Buy by Citigroup - Moomoo
MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
Why Veradermics Stock Fell Today - Quiver Quantitative
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss - BioPharma Dive
Veradermics stock jumps again on female hair loss drug win - Clinical Trials Arena
Veradermics jumps after mid-stage trial data for lead drug in female pattern hair loss - MSN
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTrade
Why is MANE stock rising today? - MSN
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $170 - Moomoo
Why Is MANE Stock Rising Today? - TradingView
Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too - Fierce Pharma
Veradermics (MANE) Sees 13.9% Increase in Stock Price - GuruFocus
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women - Yahoo Finance
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Veradermics stock rises 9% on positive hair loss trial data By Investing.com - Investing.com Canada
Veradermics (NYSE: MANE) posts strong VDPHL01 Phase 2 female data - Stock Titan
Veradermics stock rises 9% on positive hair loss trial data - Investing.com
MANE Initiates Coverage by B. Riley Securities -- Price Target S - GuruFocus
Veradermics reports phase 2 hair loss trial results By Investing.com - Investing.com Canada
Up to 90% of women reported better hair coverage by Month 6 - Stock Titan
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout - Yahoo Finance
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug - Investing.com Nigeria
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug By Investing.com - Investing.com India
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss - BioSpace
Veradermics Announces Encouraging Phase 2 Results for VDPHL01 in Female Pattern Hair Loss with Over 22 Hairs/cm² Average Growth - Kalkine Media
Veradermics to present phase 2 hair loss study results Wednesday - Investing.com
Veradermics to Share Hair Loss Drug Study Results in Wednesday Call - Moomoo
Veradermics to present phase 2 hair loss study results Wednesday By Investing.com - Investing.com Canada
MSN Money - MSN
Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $182 - Moomoo
Veradermics (MANE) Stock Forecast & Analyst Ratings - Moomoo
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom - BioSpace
MANE Should I Buy - Intellectia AI
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Index - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Value Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000E Growth Benchmark - marketscreener.com
2026 Power 25 Healthcare: Dr. Reid Waldman - Hartford Business Journal
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell Small Cap Completeness Index - marketscreener.com
Veradermics, Incorporated Actuals & Estimates (NYSE:MANE) - TradingView
Cantor Fitzgerald reiterates Veradermics stock rating after CEO dinner By Investing.com - Investing.com Australia
MANE Forecast — Price Target — Prediction for 2027 - TradingView
Veradermics Inc (MANE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):